NASDAQ$EMBC
Embecta Corp · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Embecta reported fiscal Q2 2026 revenue of $221.8M (-14% YoY) and a net loss of $4.1M ($0.07 per share).
For the quarter ended March 31, 2026, Embecta reported revenue of $221.8 million versus $259.0 million and a net loss of $4.1 million ($0.07 per share) compared with net income of $23.5 million ($0.40). Gross profit was $127.8 million; operating income was $35.0 million before interest and taxes.
- Revenue $221.8M (-14% YoY) on diabetes supply dynamics.
- Net loss $4.1M; EPS $(0.07).
- Gross profit $127.8M; operating income $35.0M.
- Interest expense $22.6M remains significant.
- Spin-off from BD continues portfolio focus on injection devices.
Headline financials
Revenue & EPS history
Embecta · Revenue · Quarterly
$222M
Forward guidance
Diabetes device market discussed around GLP-1 trends and international pricing without numeric annual EPS guide.
Tailwinds
- Positive operating income before financing costs.
Headwinds
- Top-line decline and swing to net loss.
- High interest burden post-separation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+2.6%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-8.3%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+42.9%
Q4 2024
Best reaction
-15.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.1% | -60.6% | -63.0% | |
| Q1 2026 | -7.8% | -9.3% | -20.1% | |
| Q4 2025 | -7.3% | -12.9% | -17.5% | |
| Q2 2025 | -9.7% | -12.9% | -26.4% | |
| Q1 2025 | -2.6% | -3.8% | -29.9% | |
| Q4 2024 | +42.9% | +44.6% | +44.6% | |
| Q3 2024 | +2.9% | +2.9% | +6.8% | |
| Q2 2024 | +38.7% | +42.2% | +21.1% | |
| Q1 2024 | -15.7% | -18.1% | -22.5% | |
| Q4 2023 | +7.9% | +7.1% | +14.3% | |
| Q3 2023 | -0.5% | -3.6% | -27.3% | |
| Q2 2023 | -0.7% | -3.4% | -11.8% | |
| Q1 2023 | +15.3% | +12.0% | +3.9% | |
| Q4 2020 | -1.9% | -4.3% | -15.4% | |
| Q4 2022 | -13.6% | -15.3% | -28.1% | |
| Q3 2021 | +12.7% | +16.6% | +13.3% | |
| Q3 2022 | +12.7% | +16.6% | +13.3% | |
| Q2 2022 | -12.6% | -7.7% | -6.2% | |
| Q2 2021 | -12.6% | -7.7% | -6.2% | |
| Q4 2021 | — | — | — | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro